20Aug/18
FDA Approved CAR-macrophage Therapy of Ovarian Cancer into Clinical Trials
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…